SIRT6 and neoplasm: Collectively, these findings highlight SIRT6 as a double-edged regulator in NSCLC, functioning as either an oncogene or tumor suppressor depending on the cellular context, and underscore its potential as both a prognostic biomarker and a therapeutic target.